Company Insights

NTRB customer relationships

Explore interactive graphBrowse insights index
NTRB customer relationship map

NTRB: Customer relationships that define a small-cap transdermal drug and manufacturing play

Nutriband Inc. develops transdermal pharmaceuticals and manufactures tape-based and patch products through its Pocono Pharmaceutical/Active Intell operations; the company monetizes through product sales to large retail chains and licensing/distribution deals for drug candidates (notably the AVERSA fentanyl patch). Revenue growth is currently driven by Pocono-manufactured consumer products placed into national retailers, while strategic divestitures and exclusive distribution agreements are being used to fund clinical development and commercialization of higher-margin pharmaceutical assets. Learn more about how we map third‑party relationships at the company: https://nullexposure.com/

Why these relationships matter to investors

Nutriband is operating at the intersection of two revenue models: retail manufacturing (sports/medical tapes and over-the-counter items) and pharmaceutical licensing/commercialization (AVERSA fentanyl patch upon approval). This dual posture creates distinct contracting dynamics—shorter, SKU-driven retail contracts alongside longer, regulatory-dependent distribution partnerships for drug assets. For equity holders, the key variables are manufacturing capacity at Pocono, partner cash flow for commercial rollout, and the company’s ability to monetize clinical-stage intellectual property through sales, distributions, or retained royalties.

If you want an investor-focused breakdown of these partner dynamics and source-level coverage of each relationship, start here: https://nullexposure.com/

Customer and partner map — concise, source-backed notes

Below I walk through every relationship referenced in public reporting tied to NTRB. Each entry is a plain-English summary followed by the cited source.

EarthVision Bio

Nutriband announced an agreement to sell 90% of its Pocono Pharmaceutical subsidiary to EarthVision Bio for $5.0 million, while retaining a 10% stake; the transaction was presented as a move to monetise manufacturing assets and reallocate capital. (Press release coverage by GlobeNewswire / The Globe and Mail, December 2025 / March 2026 — https://www.globenewswire.com/news-release/2025/12/29/3210959/0/en/Nutriband-Inc-Signs-Agreement-to-Sell-Majority-Stake-of-Subsidiary-Pocono-Pharmaceutical-for-5M-USD-to-EarthVision-Bio.html and https://www.theglobeandmail.com/investing/markets/stocks/NTRB-Q/pressreleases/36815949/nutriband-nasdaq-ntrb-sells-90-stake-in-pocono-pharmaceutical-for-5-million/).

Earth Vision Bio Inc. (termination notice, separate report)

A subsequent report noted termination of the sale agreement, citing non‑payment of fees by the purchaser and cancelling the prior deal. This is a material reversal to the December sale announcement and changes near-term cash expectations tied to that divestiture. (TradingView summary reporting February 13, 2026 termination — https://www.tradingview.com/news/tradingview:1179020678e46:0-nutriband-inc-terminates-sale-agreement-of-subsidiary/).

Innomedica

Nutriband signed an exclusive distribution agreement with Costa Rica-based Innomedica for AVERSA fentanyl upon approval, and for all sports tape products manufactured at Pocono Pharmaceutical/Active Intell, positioning local-market commercialization ahead of regulatory approval. (Company press releases via GlobeNewswire, Feb 17, 2026 and related filings — https://www.globenewswire.com/news-release/2026/02/17/3239119/0/en/Nutriband-Signs-Exclusive-Distribution-Agreement-with-Innomedica-for-AVERSA-Fentanyl-and-all-Sports-Tape-products-for-Costa-Rica.html).

Target (retail placement)

Nutriband reported that Pocono-manufactured products are rolling out into prominent retail locations including Target, highlighting retail distribution as a key revenue stream for the manufacturing arm. (Quarterly report summary released June 2, 2025 — https://www.globenewswire.com/news-release/2025/06/02/3091798/0/en/Nutriband-Inc-Quarterly-Report-Highlights-Record-Revenue-for-Q1-2025-up-63-YOY-and-Strategic-Progress-Toward-NDA-Filing-for-AVERSA-Fentanyl.html).

Walmart (retail placement)

Walmart is listed among national retailers receiving Pocono-manufactured products, providing scale distribution for NTRB’s consumer product revenue line. (Company Q1 2025 report via GlobeNewswire, June 2, 2025 — https://www.globenewswire.com/news-release/2025/06/02/3091798/0/en/Nutriband-Inc-Quarterly-Report-Highlights-Record-Revenue-for-Q1-2025-up-63-YOY-and-Strategic-Progress-Toward-NDA-Filing-for-AVERSA-Fentanyl.html).

Walgreens (retail placement)

Walgreens is cited as another national retail partner carrying Pocono-manufactured products, contributing to the company’s retail revenue trajectory. (Same June 2, 2025 company report — https://www.globenewswire.com/news-release/2025/06/02/3091798/0/en/Nutriband-Inc-Quarterly-Report-Highlights-Record-Revenue-for-Q1-2025-up-63-YOY-and-Strategic-Progress-Toward-NDA-Filing-for-AVERSA-Fentanyl.html).

CVS (retail placement)

CVS is included with other major chains as a distribution outlet for Pocono products, underscoring national retail penetration. (Company Q1 2025 report via GlobeNewswire, June 2, 2025 — https://www.globenewswire.com/news-release/2025/06/02/3091798/0/en/Nutriband-Inc-Quarterly-Report-Highlights-Record-Revenue-for-Q1-2025-up-63-YOY-and-Strategic-Progress-Toward-NDA-Filing-for-AVERSA-Fentanyl.html).

KT Tape

Nutriband disclosed an expanding manufacturing collaboration with KT Tape, the global kinesiology tape brand, which is positioned as a volume customer for Pocono and a driver of manufacturing utilization. (CEO letter / press release summarized December 31, 2025 — https://www.biospace.com/press-releases/nutriband-ceo-publishes-letter-to-shareholders).

What these relationships imply for operating posture

  • Contracting posture: Nutriband uses a mix of short-term retail manufacturing agreements and exclusive, regionally focused distribution contracts for drug assets. The balance favors flexible manufacturing contracts for consumer products while maintaining targeted exclusives for regulated pharmaceuticals.
  • Concentration: Retail placements across Target, Walmart, Walgreens and CVS reduce single-customer concentration risk on the consumer side, but the company’s overall revenue remains highly exposed to the operational performance of its Pocono manufacturing asset.
  • Criticality: Pocono is a critical operating asset—it supplies products that drive current revenue and is the subject of strategic M&A activity intended to unlock value. Any disruption to Pocono manufacturing or to the anticipated sale/divestiture plan materially impacts cash and growth runway.
  • Maturity: The business is early-revenue and development-stage at the pharmaceutical level: reported revenue is modest, profitability is negative, and the AVERSA asset is subject to regulatory milestones before it can meaningfully contribute to high-margin revenue.

No explicit third‑party contractual constraints were provided in the relationship results; the signals above are company-level inferences drawn from disclosed deals and retail placements.

Investment implications and near‑term catalysts

  • Near-term cash and strategic clarity depend on the Pocono transaction outcome. The December 2025 sale announcement and subsequent termination report in February 2026 create a binary outcome for expected proceeds and capital allocation.
  • Retail rollouts are the primary revenue engine today. Continued distribution into Target, Walmart, Walgreens and CVS, plus volume contracts like KT Tape, support revenue visibility while pharmaceutical work continues.
  • Regulatory and market milestones for AVERSA will be value-defining. The Innomedica distribution agreement for Costa Rica is commercially meaningful only after regulatory approval, so timelines and approvals drive longer-term upside.

For a deeper, interactive view of these partner relationships and transaction timelines, visit the company relationship hub: https://nullexposure.com/

Bottom line: where to watch

Nutriband’s value proposition is dual: cash-generating manufacturing exposure through Pocono and option value in AVERSA and related pharmaceutical IP. Investors should focus on the final status of the Pocono sale, confirmation of retail rollouts and any regulatory readings on AVERSA. Clear outcomes on the EarthVision/Pocono process and the Innomedica distribution commercialization window will be the primary catalysts.

If you want structured, source-linked intelligence for portfolio or operational due diligence, see our homepage: https://nullexposure.com/